Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conformis Inc. CFMS

Conformis Inc is an us-based medical technology company. It uses the iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped to fit each patient's anatomy. The company's iFit technology platform comprises three key elements which are iFit design, iFit printing, and iFit just-in-time delivery. It offers various partial and total knee replacement implants which include iTotal CR, iTotal PS, iDuo, and iUni. The company operates in the segment of the knee replacement market. Its total revenue is generated from the sale of its products to hospitals and other medical facilities. The majority of the company's revenue comes from the United States.


Recent & Breaking News (NDAQ:CFMS)

Conformis Actera(TM) Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration

GlobeNewswire September 13, 2022

Conformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment Conference

GlobeNewswire August 29, 2022

Conformis Reports Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants

GlobeNewswire August 1, 2022

Conformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

GlobeNewswire July 28, 2022

Conformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

GlobeNewswire July 5, 2022

Conformis Highlights New Clinical Study Findings that Knee Shapes are Highly Individualized and are Not Determined by Identifiers, Including Gender, Body Type, or Ethnicity

GlobeNewswire May 24, 2022

Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire May 10, 2022

Conformis Reports First Quarter 2022 Financial Results

GlobeNewswire May 4, 2022

Conformis, Inc. to Release First Quarter 2022 Financial Results on May 4, 2022

GlobeNewswire April 11, 2022

Conformis, Inc. Appoints Michael Fillion as Chief Operating Officer

GlobeNewswire April 1, 2022

Conformis Partners with Synchrony to Offer CareCredit Financial Services to Orthopedic Patients

GlobeNewswire March 22, 2022

Conformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate Secretary

GlobeNewswire March 14, 2022

Gary Fischetti nominated to join Conformis' Board of Directors

GlobeNewswire March 11, 2022

Conformis, Inc. Reports Fourth Quarter and Year End 2021 Financial Results

GlobeNewswire March 2, 2022

Conformis Suspends All Distribution Operations and Business Development in Russia

GlobeNewswire March 2, 2022

New Clinical Study Finds Bilateral Knee Patients Prefer Conformis' Fully Personalized Solution Over Competitive Off-the-Shelf Implants by a Factor of Over 10 to 1

GlobeNewswire February 28, 2022

Conformis iTotal® CR Knee Replacement System Awarded "7A" Performance Rating from the U.K.'s Orthopaedic Data Evaluation Panel

GlobeNewswire February 24, 2022

Conformis, Inc. to Participate in Upcoming Investor Conferences

GlobeNewswire February 18, 2022

Conformis, Inc. to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 2, 2022

GlobeNewswire January 20, 2022